SERVICES
Our service lines
From capital‑markets origination to post‑deal value capture, BRESLIN delivers a full‑spectrum corporate‑finance platform that fuels strategic growth across the life‑sciences landscape and adjacent innovation verticals. Our partners have executed multibillion‑euro buyouts, growth‑equity rounds, carve‑outs, and dual‑track IPO processes on exchanges from NASDAQ to SIX, structuring funding solutions that balance dilution, governance, and regulatory optics. As an early architect of Europe’s private‑equity secondary market, we also unlock liquidity and portfolio‑rebalancing options for limited partners, family offices, corporates, and founders—designing GP‑ and LP‑led transactions that recycle capital without compromising upside. Beyond headline financings, we incubate and spin off science‑driven businesses, pair them with strategic acquirers or co‑development partners, and deploy rigorous valuation and financial‑engineering toolkits to optimise IP monetisation. Whether identifying seed‑stage breakthroughs or shepherding late‑stage assets toward an exit, we combine sector‑mapped intelligence, investor reach, and operational playbooks to create resilient capital structures and enduring enterprise value for every client we serve.
Finance
BRESLIN provides expert financial advisory and transaction support, leveraging extensive industry experience to drive successful outcomes in complex financial operations.
- Capital Raising: Assisting companies in securing funding from institutional investors, venture capital, and private equity to fuel growth and expansion.
- Mergers & Acquisitions (M&A): Structuring and executing strategic acquisitions, divestitures, and mergers to enhance corporate value and market positioning.
- Buyouts: Facilitating management and leveraged buyouts, ensuring seamless ownership transitions with optimised financial strategies.
- Initial Public Offerings (IPOs): Guiding companies through the IPO process, from preparation and regulatory compliance to market positioning and investor engagement.
- Financial Structuring: Designing tailored financial solutions to optimise capital allocation, debt financing, and risk management strategies.
With a proven track record of successfully closing over 80 transactions, our dedicated investment, advisory, and transaction teams provide in-depth expertise and strategic insights to maximise value creation for our clients.
Secondary Transactions
BRESLIN designs custom liquidity and portfolio‑optimisation solutions that let investors free up capital without losing future upside. From GP‑led continuation funds and LP stake sales to preferred‑equity deals, we combine precise valuations, thorough due diligence, and smart tax planning to deliver clear pricing and smooth execution for institutions, corporates, and private wealth managers. The outcome: stronger balance‑sheet flexibility and a reshaped risk‑return profile that keeps portfolios aligned with changing goals.
Business Development
Drawing on unrivalled sector insight and a global‑reach network that spans Big Pharma boardrooms, cutting‑edge biotech clusters, and specialised life‑science investors, BRESLIN orchestrates business‑development initiatives that convert scientific potential into commercial traction. We source, structure, and negotiate value‑accretive partnerships – from co‑development pacts and revenue‑share alliances to in‑ and out‑licensing arrangements that monetise intellectual‑property portfolios – while embedding operational playbooks that ready assets for rapid scale.
We further support companies in expanding into new markets, refining their competitive positioning, and navigating complex regulatory landscapes. By providing strategic and operational guidance, as well as direct access to key industry stakeholders and investors, we empower clients to strengthen their market presence, enhance competitiveness, and capitalize on emerging opportunities within the life sciences industry.
Corporate Development – Spin-offs
When a promising discovery is ready to step out of the lab, BRESLIN turns it into a stand‑alone business that can thrive in real‑world markets. We map out a commercial story investors can rally behind, assemble the right cap‑table from seed onward, lock down freedom‑to‑operate on the IP, and plug in an interim leadership team that can hit revenue milestones from day one. Our cross‑border network streamlines everything from term‑sheet negotiations to first‑in‑human trials, so founders stay focused on science while we choreograph scale‑up, strategic partnerships, and dual‑track exit readiness – all with an eye toward building a company that lasts, not just a transaction that closes.
Investment Activities
BRESLIN focuses on seed to early-stage investments as well as academic and industrial spin-offs, identifying and supporting high-potential ventures that drive technological innovation and market transformation. Leveraging deep industry expertise and a strong investment track record, we provide not only capital but also strategic guidance to help emerging companies navigate critical growth stages. By fostering innovation and connecting entrepreneurs with key stakeholders, we ensure that our investments generate long-term value and sustainable success.
Exited Portfolio Companies
- Actelion, Switzerland
- Anawa Laboratories, Switzerland
- Cardion, Germany
- Develogen, Germany
- Glycart, Switzerland
- GPC Biotech, Germany
- Igeneon, Austria
- Switch Biotech, Germany
Current Porfolio
- Amypopharma, Italy
- CoBaLT GmbH, Germany
- Memo Therapeutics, Switzerland
- Qithera GmbH, Germany
Trusted by leading industry players for strategic advisory and transaction support:
